Resveratrol in Cancer Treatment with a Focus on Breast Cancer

Kowsari, Hamed; Davoodvandi, Amirhossein; Dashti, Fatemeh; Mirazimi, Seyed Mohamad Ali; Bahabadi, Zahra Razaghi; Aschner, Michael; Sahebkar, Amirhossein; Gilasi, Hamid Reza; Hamblin, Michael R.; Mirzaei, Hamed

doi:10.2174/1874467215666220616145216

Cited by 6 publications

(4 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results indicate the cytotoxic effectiveness of compound RV in suppressing the growth of MCF7 cells at micromolar range. Our findings suggest that the compound RV has the potential to inhibit the proliferation of cancerous cells and resonate with the previous reports of cytotoxicity of RV on similar or other cancer cells [56][57][58][59].…”

Section: Cell Proliferation Assaysupporting

confidence: 92%

Repurposing Resveratrol: A Novel Approach to Inhibit MTH1 for Effective Breast Cancer Therapy

Taiyab,

Haider,

Choudhury

et al. 2024

Preprint

View full text Add to dashboard Cite

The increased metabolic activity in cancer cells often leads to higher levels of reactive oxygen species (ROS) compared to normal cells, which can cause damage to cellular components, including DNA. Cancer cells rely on MTH1 to maintain their DNA integrity and cellular function to counteract this damage. MTH1 is critical in sanitizing oxidized nucleotide pools by removing damaged nucleotides. Inhibition of MTH1 disrupts this repair process, leading to increased DNA damage and cell death in cancer cells. In this study, we present resveratrol (RV) as a potential MTH1 inhibitor. Docking and MD Simulations illustrated the effective binding of RV to the active site of the MTH1 protein, forming a notably stable complex. The fluorescence binding studies estimated a high binding affinity of RV with MTH1 (Ka − 6.2 x 105), inhibiting MTH1 activity with IC50 20.4µM. The inhibitory effects of RV on the proliferation of breast cancer cells revealed significant inhibition in cell growth, leading to apoptosis. RV significantly increases ROS production, inducing considerable oxidative stress and ultimately resulting in cell death. Our study offers a rationale for evaluating RV as an MTH1 inhibitor for potential anti-cancer therapy, particularly in breast cancer.

show abstract

Section: Cell Proliferation Assaysupporting

confidence: 92%

Repurposing Resveratrol: A Novel Approach to Inhibit MTH1 for Effective Breast Cancer Therapy

Taiyab,

Haider,

Choudhury

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Recently, significant progress has been achieved in screening small molecule compounds for the treatment of BRCA with the advent of drug databases. [ 40 , 41 ] We obtained 6 compounds that may be more sensitive to high-risk BRCA patients by screening of the CTRP and PRISM databases. KX2 − 391 is an inhibitor of Src and pretubulin, which could inhibit BRCA growth and metastasis.…”

Section: Discussionmentioning

confidence: 99%

Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer

Zhu

2023

Medicine

View full text Add to dashboard Cite

Breast cancer (BRCA) is the most fatal malignancy of women. Immunotherapy has greatly improved the prognosis of advanced BRCA. Cellular senescence contributes to tumorigenesis and suppresses anti-cancer immunity. Identification of senescence-relevant long noncoding RNAs (SRlncRNAs) signature may benefit the predictions of prognosis and response to immunotherapy of BRCA. RNA-seq, mutation, and clinical data of BRCA were acquired from public databases. SRlncRNAs were screened using univariate Cox regression analysis. Consensus clustering classified BRCA patients into 2 clusters, and the differences of overall survival (OS) and immune status between the 2 clusters were analyzed by survival analysis, CIBERSORT, and ESITIMATE. The SRlncRNAs signature was constructed by least absolute shrinkage and selection operator (LASSO) regression analysis, and BRCA patients were divided into 2 risk groups. Enrichment analyses were performed to explore the cancer- and immunotherapy-relevant pathways. Transcriptome analysis was performed to investigate the differences of OS, immune infiltration, and ESITIMATE score of the 2 groups. Genome analysis was applied to investigate the differences of somatic mutation, tumor mutation burden (TMB) and microsatellite instability (MSI) between the 2 risk groups. A nomogram combined with calibration curves and decision curve analysis (DCA) was established for better clinical decision. Tumor Immune Dysfunction and Exclusion (TIDE) score and IMvigor-210 were applied for the predicting of response to immunotherapy. Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) and the Cancer Therapeutics Response Portal resource (CTRP) databases were used for drug susceptibility analysis. Ten prognostic SRlncRNAs were identified and BRCA patients were divided into 2 clusters. Cluster 1 had better OS with anti-tumor immune microenvironment. The high-risk BRCA had poorer OS in the Cancer Genome Atlas (TCGA) training cohort, which was also verified by TCGA validation cohort and GSE20685 validation cohort. Low-risk patients also had anti-tumor immune microenvironment. Genome analysis demonstrated that the high-risk group had significant higher TMB. High-risk BRCA were more susceptive to immunotherapy according to the TIDE score and IMvigor-210. Finally, drug susceptibility analysis showed that 6 compounds were sensitive to high-risk BRCA patients. We developed and verified an original SRlncRNAs signature by multi-omics analysis, which could serve as a prognosis and immunotherapy predictor for BRCA.

show abstract

“…Significantly, there is a pronounced cell cycle arrest in the S phase in both cell groups. Resveratrol negatively regulates the growth of prostate cancer cells by impacting the generation process and promoting programmed cell death in the prostate [38,39], and resveratrol prevents cell proliferation and stimulates programmed cell death in human breast cancer cells (MCF-7) [40].…”

Section: Effect Of Resveratrol Particles On the Cell Cycle Of Mcf-7 C...mentioning

confidence: 99%

Resveratrol inhibits Cell Cycle Dynamics, Caspase Activation, and Programmed Cell Death: Implications for Cancer Treatment in MCF-7 Cells"

Hamad,

Musleh,

Nasir

et al. 2024

Egyptian Journal of Veterinary Sciences

View full text Add to dashboard Cite

esveratrol is a plant-derived polyphenol known for its anti-inflammatory and anti-tumor properties in laboratory models and living organisms. Recent studies suggest that certain analogs of resveratrol may exhibit more effective anti-tumor factors. This study investigates the impact of resveratrol on the cell cycle of MCF-7 cells at concentrations of 1.5 and 2µg\ ml. Resveratrol, at 2µg\ml, significantly alters the cell cycle distribution, indicating a concentrationdependent effect. Doxorubicin serves as a positive control and induces G1 phase arrest. These results contribute to understanding the potential mechanisms of resveratrol in cancer treatment and shed light on its impact on cell cycle dynamics. Additionally, the study explores the effects of different concentrations of resveratrol on the activity of Caspase 8, using doxorubicin as a positive control for comparison. Human cell lines were exposed to varying concentrations of resveratrol (1.5 µg\ ml and 2 micrograms/ml), and Caspase 8 activities were compared with both untreated cells (control group) and those treated with doxorubicin. The average Caspase 8 activity and standard deviation were calculated for each treatment group, and the statistical significance was determined. this study highlights the concentration-dependent effects of resveratrol on the cell cycle distribution of MCF-7 cells, suggesting its potential as a therapeutic agent in cancer treatment. Furthermore, the investigation of Caspase 8 activity provides additional insight into the anti-cancer properties of resveratrol in breast cells.

show abstract

Resveratrol in Cancer Treatment with a Focus on Breast Cancer

Cited by 6 publications

References 183 publications

Repurposing Resveratrol: A Novel Approach to Inhibit MTH1 for Effective Breast Cancer Therapy

Repurposing Resveratrol: A Novel Approach to Inhibit MTH1 for Effective Breast Cancer Therapy

Multi-omics analysis revealing a senescence-relevant lncRNAs signature for the assessment of response to immunotherapy for breast cancer

Resveratrol inhibits Cell Cycle Dynamics, Caspase Activation, and Programmed Cell Death: Implications for Cancer Treatment in MCF-7 Cells"

Contact Info

Product

Resources

About